Eating Disorders News and Research

Latest Eating Disorders News and Research

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Increased SIRT1 protein can delay delay aging, extend lifespan

Researchers watched two groups of mice, both nearing the end of a two-day fast. One group was quietly huddled together, but the other group was active and alert. The difference? The second set of mice had been engineered so their brains produced more SIRT1, a protein known to play a role in aging and longevity.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

FDA approves Aricept 23 mg tablet for Alzheimer's disease

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept 23 mg tablet for the treatment of moderate-to-severe Alzheimer's disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are available

26 Jul 2010

Four areas that impact weight, obesity in women identified

The information gap and general lack of understanding of obesity's unique and disproportionate impact on women contributes to the challenges of the 65 million American women who are considered overweight or obese, said the Strategies to Overcome and Prevent (STOP) Obesity Alliance Task Force on Women at a meeting on Capitol Hill today.

22 Jul 2010

Active family engagement is important for recovery from substance abuse, chemical dependency

Active family engagement and commitment is one of the most underappreciated aspects of recovery from substance abuse and chemical dependency, according to clinical staff at Timberline Knolls Residential Treatment Center, a leading eating disorder and addiction treatment center.

16 Jul 2010

Deaths from heroin overdoses in Chicago's Cook County fall 16%: Study

A new study by Roosevelt University's Illinois Consortium on Drug Policy shows deaths from heroin overdoses in Chicago's Cook County fell 16 percent during the last decade, but the Chicago metropolitan region still ranks among the worst in the nation for heroin use. Kimberly Dennis, M.D., eating disorder specialist at Chicago's Timberline Knolls Residential Treatment Center, sees the use of heroin regularly from women and girls she treats and knows the importance of awareness and seeking help to overcome this addiction.

12 Jul 2010

Fussy eating may be an “eating disorder” say researchers

Picky and fussy eaters are not just being difficult to please say U.S. researchers. They may be suffering from an eating disorder like anorexia or bulimia. Soon the disorder is to have an official name and the American Psychiatric Association plans to call them “selective eaters”.

11 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Virtual food can be used for evaluation and treatment of eating disorders: Researchers

Food presented in a virtual reality environment causes the same emotional responses as real food. Researchers writing in BioMed Central's open access journal Annals of General Psychiatry compared the responses of people with anorexia and bulimia, and a control group, to the virtual and real-life snacks, suggesting that virtual food can be used for the evaluation and treatment of eating disorders.

5 Jul 2010

Web sites that promote anorexia raise concern

For women with low self-esteem, poor body image and a certain genetic predisposition towards an eating disorder, the messages promoted on pro-eating disorder web sites can be similar to someone considering suicide finding a loaded gun on her pillow.

3 Jul 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Elements Behavioral Health acquires The Ranch in Tennessee

Elements Behavioral Health, provider of residential treatment services for addiction and co-occurring disorders, announced this week the acquisition of The Ranch in Nunnelly, Tennessee. Elements is best known to the public as the owner of the internationally famous Promises Treatment Centers in Malibu and Los Angeles, where many Hollywood celebrities have been treated successfully for substance abuse.

2 Jul 2010

Women in early recovery gain new perspective on helping themselves by helping others

Women seeking to overcome an eating disorder or addiction still face numerous hurdles once they acknowledge their disease and commit to pursuing a path of recovery. Women with advanced or multiple interconnected diseases often seek inpatient or residential treatment, which gives them time to step back from the demands of daily life to focus solely on themselves.

1 Jul 2010

Majority of older women seek help for eating disorders

Eating disorders are equal-opportunity offenders – crossing economic and cultural boundaries and leaping the borders of age and gender. For a long time thought to be diseases affecting teens and young women in their 20s, eating disorder treatment centers nationwide are seeing an increase in the population of older women seeking help for eating disorders.

25 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

New book gives hope to women and families who are in difficult stages of anorexia treatment

Women and families struggling with an eating disorder or another addiction should never lose sight of the need to sustain the spirit, according to a new book by Jena Morrow, an author in recovery after more than 20 years with anorexia nervosa. Morrow, a behavioral health specialist at Timberline Knolls Residential Treatment Center, details a battle with anorexia that begins in early childhood in Hollow: An Unpolished Tale, recently released by Moody Publishers.

17 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Eating Disorders News and Research

Latest Eating Disorders News and Research

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Increased SIRT1 protein can delay delay aging, extend lifespan

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

FDA approves Aricept 23 mg tablet for Alzheimer's disease

Four areas that impact weight, obesity in women identified

Active family engagement is important for recovery from substance abuse, chemical dependency

Deaths from heroin overdoses in Chicago's Cook County fall 16%: Study

Fussy eating may be an “eating disorder” say researchers

Shire receives FDA approval of Daytrana for ADHD in adolescents

Virtual food can be used for evaluation and treatment of eating disorders: Researchers

Web sites that promote anorexia raise concern

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Elements Behavioral Health acquires The Ranch in Tennessee

Women in early recovery gain new perspective on helping themselves by helping others

Majority of older women seek help for eating disorders

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

New book gives hope to women and families who are in difficult stages of anorexia treatment

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Eating Disorders News and Research

Latest Eating Disorders News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in